158
Participants
Start Date
March 25, 2019
Primary Completion Date
February 26, 2020
Study Completion Date
May 25, 2020
Livoletide
Daily subcutaneous injection
Placebo
Daily subcutaneous injection
Cliniques Universitaires Saint-Luc, Brussels
Royal Prince Alfred Hospital, Camperdown
The Childrens Hospital at Westmead, Westmead
Erasmus University Medical Center, Rotterdam
Stichting Kind en Groei, Rotterdam
Austin Health, Melbourne
Perth Children's Hospital, Nedlands
New York Presbyterian Morgan Stanley Children's Hospital, New York
Winthrop University Hospital, Mineola
Johns Hopkins University, Baltimore
CHU de Toulouse - Hospital Rangueil, Toulouse
University of Alabama at Birmingham, Birmingham
Vanderbilt University Medical Center, Nashville
University of Michigan, Ann Arbor
Hospital de Cruces, Barakaldo
Centre Hospitalier Universitaire d'Angers, Angers
Children's Hospitals and Clinics of Minnesota-Minneapolis, Saint Paul
University of Kansas Medical Center, Kansas City
CHU Lyon - Hopital Femmes Mere Enfant, Bron
Hospital Pitie Salpetriere, Paris
Hopital Necker-Enfants Malades, Paris
University of Texas Southwestern Medical Center, Dallas
Baylor College of Medicine, Houston
Children's Hospital Colorado, Denver
Azienda Ospedaliera Universitaria Federico II, Napoli
Rady Children's Hospital - San Diego, San Diego
University of California - Irvine Medical Center, Orange
Seattle Children's Hospital, Seattle
Boston Children's Hospital, Boston
CHU de Toulouse - Hopital des Enfants, Toulouse
Ospedale Pediatrico Bambino Gesù, Roma
Hospital General Universitario de Alicante, Alicante
Hospital Sant Joan de Deu, Barcelona
Corporacio Sanitaria Parc Tauli - Hospital de Sabadell, Sabadell
NHS Tayside, Dundee
Chelsea and Westminster Hospital, London
Imperial College London, London
Lead Sponsor
Millendo Therapeutics SAS
INDUSTRY